Tracers / [68Ga]DOTA-FD3
[68Ga]DOTA-FD3
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- —
- Target / mechanism
- Fibroblast activation protein (FAP) PMID 38706713
- Clinical application
- —
- Theranostic pair
- <a href="/tracers/lu177-dotafd3/">lu177-dotafd3</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | — | 94% | FD3 | 38706713 2023 Research (Wash D C) This mixture was added to 400 μl of 68GaCl3 solution (containing 37 MBq) in 0.1 M HCl, with pH adjusted to 4.0 using 0.1 M NH4OAC. The mixture was incubated at 100 °C for 10 min without any additional purification steps. |
Need this precursor?We can point you to suppliers for [68Ga]DOTA-FD3, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 38706713. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.